Eledon pharmaceuticals reports preliminary second quarter 2024 operating results

Presented updated data on 13 participants from ongoing phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in phase 2 bestow trial completed an oversubscribed $50 million private placement; company expects sufficient liquidity through december 2025 irvine, calif., aug. 14, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported recent business highlights for its second quarter 2024.
ELDN Ratings Summary
ELDN Quant Ranking